Oncology – Head and Neck
M-A of randomized trials | Prophylactic central neck lymph node dissection in low-risk thyroid carcinoma patients does not decrease the incidence of locoregional recurrence.
21 Sep, 2022 | 13:07h | UTCProphylactic Central Neck Lymph Node Dissection in Low-risk Thyroid Carcinoma Patients Does Not Decrease the Incidence of Locoregional Recurrence: A Meta-analysis of Randomized Trials – Annals of Surgery (link to abstract – $ for full-text)
Noninferiority RCT | Induction chemotherapy regimen of docetaxel plus cisplatin vs. docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma.
6 Sep, 2022 | 14:29h | UTC
Guideline | Patient preparation and radiation protection guidance for adult patients undergoing radioiodine treatment for thyroid cancer.
1 Sep, 2022 | 11:53h | UTC
RCT | In patients with low-risk nasopharyngeal carcinoma, radiotherapy alone was noninferior to radiotherapy plus concurrent chemoradiotherapy on survival without disease relapse at 3 years.
25 Aug, 2022 | 12:13h | UTCEffect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial – JAMA (free for a limited period)
Video Editor’s Note: Radiotherapy With vs Without Chemoradiotherapy in Low-risk Nasopharyngeal Carcinoma – JAMA
The contemporary management of cancers of the sinonasal tract in adults.
16 Aug, 2022 | 13:39h | UTC
Guideline | Pediatric differentiated thyroid carcinoma.
29 Jul, 2022 | 12:31h | UTC
Phase 2 RCT | Deintensified chemoradiotherapy for pretreatment Epstein-Barr Virus DNA-selected low-risk locoregionally advanced nasopharyngeal carcinoma.
19 Jul, 2022 | 12:58h | UTCDeintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentaries:
Commentary on Twitter
Less is more? 🤔 2-cycle cisplatin concurrent chemoradiotherapy is not inferior to 3-cycles based on 3-yr PFS in treating locoregionally advanced nasopharyngeal ca w/preRX EBV DNA levels < 4000.QOL & toxicity improved w/ less chemo https://t.co/XovHi2P06W pic.twitter.com/JJqiC8wnWW
— Journal of Clinical Oncology (@JCO_ASCO) January 25, 2022
Evaluation of the molecular landscape of pediatric thyroid nodules and use of a multigene genomic classifier in children.
8 Jul, 2022 | 11:20h | UTC
Commentaries on Twitter
A multigene classifier reveals that malignant pediatric thyroid nodules have a unique molecular landscape vs those in adults. The classifier had a sensitivity of 96% & specificity of 78% for cancer detection & might reduce the need for diagnostic surgery: https://t.co/hdsPjGe9IR
— NatureRevClinOncol (@NatRevClinOncol) June 16, 2022
Pediatric thyroid cancer is on the rise. Its genomic landscape is unique; but, this retrospective case series shows that it may still be amenable to molecular classification—potentially decreasing diagnostic surgery & opening avenues for targeted therapy. https://t.co/KiYMsB1qGM
— JAMA Oncology (@JAMAOnc) June 10, 2022
Induction chemotherapy in nasopharyngeal carcinoma- A systematic review of phase III clinical trials.
23 Jun, 2022 | 09:54h | UTC
Health Technology Assessment: Molecular testing for thyroid nodules of indeterminate cytology.
25 May, 2022 | 10:42h | UTC
M-A: Complication rates of total thyroidectomy vs. hemithyroidectomy for treatment of papillary thyroid microcarcinoma.
11 May, 2022 | 10:59h | UTCComplication Rates of Total Thyroidectomy vs Hemithyroidectomy for Treatment of Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-analysis – JAMA Otolaryngology-Head & Neck Surgery (link to abstract – $ for full-text)
Commentary on Twitter
In this systematic review and #meta-analysis, complications in the surgical management of micropapillary #thyroid carcinoma increased with the extent of surgery performed, although complications and recurrence were low for both operations. https://t.co/Itf14o38Vu @wiscsurgery
— JAMA Otolaryngology – Head & Neck Surgery (@JAMAOto) May 6, 2022
ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer.
5 May, 2022 | 10:16h | UTC
RCT: Effect of capecitabine maintenance therapy plus best supportive care vs. best supportive care alone on progression-free survival among patients with newly diagnosed metastatic nasopharyngeal carcinoma who had received induction chemotherapy.
27 Apr, 2022 | 07:44h | UTCEffect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy: A Phase 3 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Randomized trial of efficacy and safety of capecitabine maintenance therapy in metastatic nasopharyngeal carcinoma demonstrates that capecitabine maintenance therapy improved survival & was associated with manageable toxicities. https://t.co/Ay2WZ7ZuCN pic.twitter.com/sZJ6qfzCOY
— JAMA Oncology (@JAMAOnc) February 17, 2022
RCT: Sintilimab vs. placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic esophageal squamous cell carcinoma.
20 Apr, 2022 | 09:28h | UTC
Commentary on Twitter
Compared with placebo, sintilimab in combination with chemo showed significant benefits in overall survival and progression free survival as first line treatment in patients with advanced or metastatic oesophageal squamous cell carcinoma, finds study https://t.co/m8Gn3SBmCu
— The BMJ (@bmj_latest) April 19, 2022
Development and validation of machine learning models for predicting occult nodal metastasis in early-stage oral cavity squamous cell carcinoma.
20 Apr, 2022 | 09:14h | UTC
Commentary on Twitter
In this diagnostic modeling study, #MachineLearning models built with multi-institutional data showed potential to reduce morbidity from elective neck dissections with similar cancer outcomes in patients with early-stage oral cavity squamous cell carcinoma https://t.co/aRktgc0ms6
— JAMA Network Open (@JAMANetworkOpen) April 13, 2022
Development and validation of a decision analytical model for posttreatment surveillance for patients with oropharyngeal carcinoma.
14 Apr, 2022 | 07:52h | UTC
RCT: Effect of induction chemotherapy with Paclitaxel, Cisplatin, and Capecitabine vs. Cisplatin and Fluorouracil on failure-free survival for patients with stage IVA to IVB Nasopharyngeal Carcinoma.
28 Mar, 2022 | 08:36h | UTCEffect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary: Triplet Induction Regimen Bests Doublet for Nasopharyngeal Carcinoma — Three drugs reduced risk of disease failure, but longer follow-up needed to assess OS – MedPage Today (free registration required)
Commentary on Twitter
Phase 3 randomized trial of paitents with stage IVA to IVB nasopharyngeal carcinoma shows that induction chemotherapy w 2 cycles of paclitaxel/cisplatin/capecitabine improved failure-free survival vs. cisplatin/5-FU before concurrent chemoradiation. https://t.co/YYEvFsTxgd pic.twitter.com/7qbSXLWCE1
— JAMA Oncology (@JAMAOnc) March 24, 2022
SEOM-TTCC clinical guideline in nasopharynx cancer.
25 Mar, 2022 | 08:20h | UTCSEOM-TTCC clinical guideline in nasopharynx cancer (2021) – Clinical and Translational Oncology
Trends in HPV–associated cancers, demographic characteristics, and vaccinations in the US, 2001-2017.
17 Mar, 2022 | 08:16h | UTCAuthor Interview: Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations
Related:
Three-year follow-up of 2-dose versus 3-dose HPV vaccine
CDC: 92% of Human Papillomavirus–Attributable Cancers can be Targeted by HPV Vaccination
Meta-Analysis: Population-level Impact of HPV Vaccination Programs
RCT: In patients with low-risk thyroid cancer, thyroidectomy without ablation radioiodine was noninferior to thyroidectomy with ablation radioiodine at 3 years.
10 Mar, 2022 | 10:59h | UTCThyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: New research casts doubt on a cornerstone of thyroid cancer treatment – STAT
Commentary on Twitter
In RCT involving patients with low-risk differentiated thyroid cancer undergoing thyroidectomy, a follow-up strategy that did not involve the use of radioiodine was noninferior to the use of radioiodine in the response to treatment at 3 years. https://t.co/RaJL3tdE4T pic.twitter.com/8nIPw50nkg
— NEJM (@NEJM) March 9, 2022
RCT: Elective upper-neck vs. whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma.
9 Mar, 2022 | 08:17h | UTCElective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentaries:
Elective Upper-Neck vs Whole-Neck Irradiation in Nasopharyngeal Carcinoma – The ASCO Post
Lower Neck-Sparing RT Succeeds in Nasopharyngeal Carcinoma— Phase III trial also shows that upper-neck irradiation leads to fewer late toxicities – MedPage Today (link to abstract – $ for full-text)
RCT: In operated patients with head and neck cancer, chemoradiotherapy with weekly cisplatin is noninferior to 3-weekly cisplatin and is associated with reduced toxicity.
3 Mar, 2022 | 08:11h | UTC
Commentary from the author on Twitter
Dear friends,
Finally, the results of JCOG1008, post operative CRT (weekly CDDP vs. 3-weekly CDDP) has published on Journal of Oncology.
Weekly CDDP+RT is a new treatment option with equal efficacy and better safety profile.
Please check the manuscript!!https://t.co/XG6mkGeo4Y— Naomi Kiyota (@kiyota_naomi) March 1, 2022
HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management.
1 Mar, 2022 | 08:30h | UTCHPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management – Nature Reviews Clinical Oncology (if the link is paywalled, try this one)
Consensus Statement: Head and neck cancer survivorship.
16 Feb, 2022 | 08:49h | UTCRelated:
Head and Neck Cancer Survivorship Care Guideline
American Cancer Society Head and Neck Cancer Survivorship Care Guideline
ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?
11 Feb, 2022 | 08:23h | UTC